• Explore /
  • Poster
  • / A phase II, randomized, open-label 3-arm clinical trial of fulvestrant (F) plus goserelin (G) versus anastrozole (A) plus goserelin (G) versus goserelin (G) alone for hormone receptor (HR) positive, tamoxifen (T) pretreated premenopausal women with recurrent or metastatic breast cance r(MBC) (KCSG BR10-04).

A phase II, randomized, open-label 3-arm clinical trial of fulvestrant (F) plus goserelin (G) versus anastrozole (A) plus goserelin (G) versus goserelin (G) alone for hormone receptor (HR) positive, tamoxifen (T) pretreated premenopausal women with recurrent or metastatic breast cance r(MBC) (KCSG BR10-04).

Abstract Poster

Authors

null

Ji-Yeon Kim

Samsung Medical Center, Seoul, Republic of Korea

Ji-Yeon Kim , Seock-Ah Im , Kyung Hae Jung , Jungsil Ro , Joohyuk Sohn , Jee Hyun Kim , Yeon Hee Park , Tae Yong Kim , Sung-Bae Kim , Keun-Seok Lee , Gun Min Kim , Se Hyun Kim , Jin Seok Ahn , Kyung-Hun Lee , Jin-Hee Ahn , In Hae Park , Young-Hyuck Im

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT01266213

Citation

J Clin Oncol 35, 2017 (suppl; abstr 1041)

DOI

10.1200/JCO.2017.35.15_suppl.1041

Abstract #

1041

Poster Bd #

33

Abstract Disclosures

Similar Posters

First Author: Oana Cristina Danciu

First Author: Alicia Frances Clare Okines

First Author: Nicholas Patrick McAndrew

First Author: Senthil Damodaran